QIAGEN demonstrates expanded bioinformatics workflows at ASHG meeting

QIAGEN has announced a number of new capabilities for its Ingenuity Variant Analysis and CLC Cancer Research Workbench solutions that accelerate the workflows for researchers to move from sample to insight with next generation sequencing (NGS). The company is demonstrating the latest workflows for analysis and interpretation of NGS data, focused on hereditary disease and detection of somatic driver mutations in cancer, at the American Society of Human Genetics (ASHG) annual meeting in San Diego, California.

QIAGEN’s Ingenuity Variant Analysis is a web-based software application that filters genetic variants in a secure, private, cloud-based environment to identify variants most likely to cause disease. Ingenuity applications provide researchers a platform to efficiently evaluate data generated by high-throughput NGS technologies. Ingenuity Variant Analysis leverages the Ingenuity Knowledge Base, a repository of curated biological interactions and functional annotations created from millions of individually modeled relationships among proteins, genes, complexes, cells, tissues, drugs, and diseases.

QIAGEN’s CLC Cancer Research Workbench, a comprehensive and customizable cancer-focused informatics solution, provides scientists and clinicians with tools to discover prognostic markers, identify subclonal somatic mutations, detect inherited traits, find biomarkers for drug response, and determine new oncogenes. All results can be filtered, visualized, and compared with relevant databases. Users will also be able to detect copy number variations (CNVs) and variants from RNA-seq data, which can be further analyzed using Ingenuity Variant Analysis for causal variant identification. QIAGEN has also developed the “FastQ-to-insight solution,” which integrates CLC Cancer Research Workbench directly with Ingenuity Variant Analysis. The new Workbench plug-in allows users to identify and interpret somatic cancer driver mutations using Ingenuity Variant Analysis and to visualize the results in both products to identify and validate the best candidates. This new tool is being demonstrated at ASHG, and the product’s launch is expected at the end of October. Learn more about solutions from QIAGEN.